Finally, another clinical study with adults with T2DM who were treated with a sodium glucose co-transporter-2 (SGLT-2) inhibitor and were randomly assigned to receive subcutaneous semaglutide (1.0 mg) or placebo once weekly for 30 weeks showed that adding semaglutide to SGLT-2 inhibitor therapy significantly reduce bodyweight (SUSTAIN 9, NCT03086330) [45]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.